25 May 2013
Keywords: Rheumatoid arthritis, Biologicals, Roche, Chugai, Actemra, Roctemra, AstraZeneda, Pfizer, Decision Resources
Article | 30 July 2010
In the rheumatoid arthritis (RA) drug market, the uptake of alternative biologics such as Roche/Chugai's Actemra/RoActemra (tocilizumab) will ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.